TD Cowen analyst Dan Brennan raised the firm’s price target on GeneDx to $50 from $46 and keeps a Buy rating on the shares. The firm posted a sales beat as the shift to higher priced exomes/ genomes continues and the value proposition for GeneDx becomes clearer with each passing quarter.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on WGS: